Mechanisms of androgen receptor-centered transcriptional networks in regulating cd8+ t cell exhaustion and therapeutic applications in cancer
US-2024382459-A1 · Nov 21, 2024 · US
Angiogenesis inhibitors
US8980930B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980930-B2 |
| Application number | US-63059605-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 27, 2005 |
| Priority date | Jun 25, 2004 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
First claim
Opening claim text (preview).
What is claimed: 1. A method of inhibiting angiogenesis in undesired tissue in a subject consisting of administering to the subject an effective amount of itraconazole. 2. The method of claim 1 , wherein the compound is administered for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or ocular inflammatory disorders. 3. The method of cl…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980930B2 cover?
- Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
- Who is the assignee on this patent?
- Liu Jun, Chong Curtis, Sullivan David J, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/58. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).